Galectin Therapeutics Belapectin NAVIGATE Trial EASL 2026 (May 27): New Oral and Poster Analyses on Disease-Modification Potential in Advanced MASH Cirrhosis
Galectin Therapeutics announced oral and poster presentations today at EASL 2026 covering new analyses from the global Phase 3 NAVIGATE trial of belapectin in advanced MASH cirrhosis. Belapectin is a galectin-3 inhibitor (a carbohydrate-based, not strictly peptide, therapeutic) developed for compensated MASH cirrhosis — the indication that current FDA-approved MASH therapies (Madrigal's Rezdiffra, August 2025-approved semaglutide) do not yet directly address. The NAVIGATE trial is designed to demonstrate disease-modification potential in compensated MASH cirrhosis (F4c) — the patient population at highest risk of progression to decompensated cirrhosis and hepatocellular carcinoma. The Galectin data sits alongside Madrigal's parallel EASL data on Rezdiffra cardiovascular and portal-hypertension markers from MAESTRO-NASH/MAESTRO-NAFLD-1 secondary analyses, completing the non-peptide MASH-treatment context for the GLP-1/glucagon peptide programs at the meeting.